Foundational Bio

Cover Block

PUBLIC

Name	Foundational Bio
Tagline	Building a self-driving lab: an AI-native, fully automated laboratory for life-science experimentation. [Foundational Bio, retrieved 2024]
Headquarters	New York
Industry	Deeptech
Technology	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

This initial snapshot shows a venture-scale deeptech company operating from New York with a focus on AI-driven laboratory automation. The company's public presence is anchored by its stated mission to build a fully automated, AI-native lab, though key details on its founding timeline and business model are not yet in the public record.

Links

PUBLIC

• Website: https://foundational.bio/

Data Accuracy: GREEN -- Confirmed by company website [Foundational Bio, retrieved 2024].

Executive Summary

PUBLIC Foundational Bio is pursuing an AI-native, fully automated laboratory platform, a concept known as a self-driving lab, aimed at accelerating discovery in the life sciences by replacing manual experimental workflows [Foundational Bio, retrieved 2024]. The ambition to automate complex, iterative R&D processes represents a high-conviction bet within deeptech, seeking to address a persistent bottleneck in biopharma productivity. The company's public presence is minimal, anchored by a website and support from established early-stage investors SOSV and Boost VC, though specific funding terms and corporate structure remain undisclosed. Its differentiation is proposed to stem from a fully integrated, AI-driven approach to laboratory automation, a field that academic literature suggests is advancing through cloud infrastructure and multi-agent systems [ScienceDirect, 2025]. The founding team, Tomaz Berisa and Jahan-Yar Parsa, lacks publicly detailed biographies, making an assessment of their operational or technical experience in lab automation or biotech challenging. Over the next 12-18 months, the critical milestones to watch are the transition from concept to a demonstrable technical prototype, the articulation of a clear initial customer segment, and any subsequent capital raise that would provide validation and resources for development.

Data Accuracy: YELLOW -- Core company description is from its own website; investor backing is listed but funding details are unconfirmed. Founders are named but backgrounds are not publicly detailed.

Taxonomy Snapshot

Axis	Value
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

Foundational Bio is a New York-based entity building a self-driving laboratory for life-science experimentation [Foundational Bio, retrieved 2024]. The company’s public presence is limited, with its website providing the core description of an AI-native, fully automated lab designed to replace manual workflows [Foundational Bio, retrieved 2024]. Founders Tomaz Berisa and Jahan-Yar Parsa are listed as team members, and the company has received support from investors SOSV and Boost VC.

A chronological sequence of public milestones is not available. The company has not announced a formal founding date, funding rounds, or product launch events through standard media channels. The available information positions the company in a pre-launch or early operational stage, with its primary public footprint consisting of a basic website and investor affiliations.

Data Accuracy: YELLOW -- Key company descriptors are from its own website; investor affiliations are listed but no funding details are publicly verified.

Product and Technology

MIXED The core concept is an AI-native, fully automated laboratory designed to replace manual workflows in life-science experimentation. According to the company's own description, this "self-driving lab" aims to increase both the speed and reliability of discovery processes [Foundational Bio, retrieved 2024]. The vision aligns with broader industry research into cloud-based biofoundries where multi-AI agents collaborate to advance automated experimentation [ScienceDirect, 2025].

Specific implementation details, such as the types of experiments targeted, the physical hardware involved, or the proprietary AI models powering the automation, are not publicly available. The company's public footprint does not include technical whitepapers, case studies, or product demos that would allow for a deeper assessment of the technology stack. The named investors, SOSV and Boost VC, have a track record in deeptech and frontier technology, which provides indirect, contextual support for the technical ambition.

PUBLIC The promise of automating the scientific method itself is reshaping the economics of discovery, moving life sciences from a craft to a scalable industrial process. Foundational Bio's ambition sits at the convergence of two high-growth, high-investment domains: laboratory automation and AI-driven drug discovery. While the company's specific market position is not quantified, the broader ecosystem it aims to enter is defined by substantial capital flows and clear, urgent demand signals.

Demand for automated experimentation is driven by the persistent inefficiency of traditional R&D. The pharmaceutical industry's R&D productivity, as measured by the number of new drugs approved per billion dollars spent, has been in long-term decline, a trend often referred to as Eroom's Law (the inverse of Moore's Law) [Nature Reviews Drug Discovery, 2012]. This creates a powerful economic incentive to adopt tools that can compress discovery timelines and reduce costly manual labor. Concurrently, the rapid maturation of AI models capable of generating novel molecular structures and predicting biological interactions has created a need for high-throughput, reliable physical validation,a bottleneck that automated labs are designed to address. The cited research notes that cloud biofoundries and multi-AI agent systems are advancing the field by enabling collaboration and distributed experimentation [ScienceDirect, 2025].

Quantifying the total addressable market for a 'self-driving lab' is challenging, as it is an emerging category. Analysts can triangulate using adjacent markets. The global laboratory automation market was valued at approximately $6.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 6% through the next decade, driven by pharmaceutical and biotechnology R&D demand [Grand View Research, 2024]. More directly, the market for AI in drug discovery is forecast to exceed $5 billion by 2028, growing at a CAGR of nearly 30% [MarketsandMarkets, 2023]. Foundational Bio's solution, if successful, would capture value from segments of both these multi-billion dollar markets.

Regulatory and macro forces present a complex landscape. On one hand, regulatory bodies like the U.S. Food and Drug Administration are increasingly issuing guidance on the use of AI and machine learning in drug development, which could provide a clearer pathway for AI-native discovery platforms [FDA, 2023]. On the other hand, the capital-intensive nature of building and operating automated wet labs presents significant barriers to entry and scaling. Furthermore, the current high-interest-rate environment has tightened funding for capital-heavy deeptech ventures, potentially lengthening the runway to commercialization for hardware-integrated platforms like Foundational Bio's proposed system.

Lab Automation (2023) | 6.5 | $B
AI in Drug Discovery (2028E) | 5.2 | $B

The projected growth rates of these two adjacent markets,steady for lab automation and explosive for AI in drug discovery,highlight where investor excitement and capital allocation are concentrated. The substantial size of the established automation market provides a baseline for revenue potential, while the faster-growing AI segment points to the premium placed on intelligent, software-driven discovery tools.

Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous, third-party industry reports; direct TAM/SAM for the specific 'self-driving lab' category is not publicly available from named sources.

Competitive Landscape

MIXED

Foundational Bio enters a field where the term "self-driving lab" is used by several distinct types of companies, from AI-native software platforms to integrated hardware-automation providers. The competitive map is best understood by separating the layers of the technology stack.

• AI-native drug discovery platforms. These are software-first companies that use AI to design molecules or predict biological interactions, often partnering with contract research organizations (CROs) for wet-lab validation. Formation Bio, a well-funded entity that raised a $372 million Series D in June 2024, exemplifies this model, focusing on AI-driven clinical development [Formation Bio]. Recursion Pharmaceuticals operates a similar platform, integrating automated cell imaging and AI for drug discovery, but its approach is built around its own internal pipeline rather than as a service [Crunchbase].
• Integrated automation providers. This segment includes companies that build the physical hardware and robotics for lab automation. Their differentiation is in the physical integration and operational scale of automated workflows.
• Foundation model developers. A newer adjacent category includes startups like Blank Bio (a Y Combinator graduate), which is building RNA foundation models [Blank Bio]. These companies provide the underlying AI models that could power a self-driving lab's predictive capabilities, positioning them as potential partners or upstream competitors.

Where Foundational Bio claims a defensible edge is in its proposed integration of these layers into a single, "AI-native and fully automated" system [Foundational Bio, retrieved 2024]. The concept of a cloud biofoundry, where multi-AI agents collaborate to advance experiments, represents a forward-looking architectural bet [ScienceDirect, 2025]. This edge is currently perishable, however, as it exists only as a concept on a website; it is not yet validated by public deployments, proprietary datasets, or patented integration methods. The company's early backing by SOSV and Boost VC provides some capital runway to build this integration, but it is a fraction of the resources available to established players.

The company is most exposed on two fronts. First, it lacks the clinical development expertise and regulatory experience of a Formation Bio, which has a rebranded history as TrialSpark and a focus on running clinical trials. Second, it does not appear to own the physical automation layer, which is capital-intensive and requires deep engineering in robotics and lab hardware. Without a clear moat in either the AI algorithms or the robotic systems, Foundational Bio risks being positioned as an integrator in a market where specialists dominate each layer.

The most plausible 18-month scenario hinges on execution speed. If Foundational Bio can rapidly demonstrate a working, closed-loop system with a novel dataset or a unique automation approach, it could attract a strategic partnership with a large pharma company seeking to outsource early-stage discovery. The winner in this case would be a platform like Blank Bio, whose foundational models could become the industry-standard AI engine, making integration layers more commoditized. Conversely, if integration proves slower than expected, Foundational Bio becomes a loser in a market where well-funded incumbents like Recursion continue to scale their own automated platforms internally, and cloud lab providers like Emerald Cloud Lab expand their service offerings to include more AI-driven experiment design.

Data Accuracy: YELLOW -- Competitor descriptions are drawn from public sources, but Foundational Bio's own positioning is inferred from limited first-party material.

Opportunity

PUBLIC

The ultimate prize for a company that successfully automates discovery is a fundamental reordering of the economics and speed of the life sciences industry.

The headline opportunity for Foundational Bio is to become the category-defining infrastructure for automated, AI-native research and development. This is not simply a tool to make existing labs incrementally faster; it is a bet on a new paradigm where the laboratory itself is a software-defined, autonomous system. The company's stated goal is to replace manual workflows to increase the speed and reliability of experimentation [Foundational Bio, retrieved 2024]. If executed, this could shift the locus of innovation from manual, capital-intensive lab operations to scalable, code-driven discovery platforms. The reachable outcome is a platform that serves as the default operating system for a new generation of biotech and pharmaceutical R&D, capturing value not just from software licensing but from a share of the accelerated discovery pipeline itself.

Growth would likely follow one of several distinct, high-conviction paths, each with a clear catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Platform Partner for Big Pharma	Foundational Bio's self-driving lab is adopted as a central, outsourced discovery engine by a top-10 pharmaceutical company, moving from a pilot to a multi-year, nine-figure partnership.	A successful, de-risked pilot project with a named partner that demonstrates a material reduction in cycle time for a specific therapeutic program.	The industry trend toward external innovation and AI-driven discovery is well-established, with large pharma actively seeking productivity gains [ScienceDirect, 2025]. A comparable, Formation Bio, has structured major collaborations based on its AI-native approach [Formation Bio].
The Cloud Biofoundry Standard	The company's architecture becomes the de facto technical standard for cloud-native, automated life science research, akin to what AWS became for compute infrastructure.	The open-sourcing or widespread licensing of a key software layer that creates a developer ecosystem and locks in instrumentation partners.	The concept of cloud biofoundries enabling multi-AI agent collaboration is an active area of academic and commercial research, suggesting a readiness for standardized platforms [ScienceDirect, 2025].

Compounding in this model would be driven by a data and execution flywheel. Each experiment run on the platform generates structured, machine-readable data that improves the underlying AI models' predictive power. Better models design more effective subsequent experiments, which in turn attract more users and programs to the platform. This creates a classic data moat: the system that runs the most experiments learns the fastest, making it increasingly difficult for new entrants or manual processes to compete on cost or success rate. While there is no public evidence this flywheel is already spinning for Foundational Bio, the technical premise is that the platform's design is inherently geared to initiate this virtuous cycle from its first automated run.

The size of the win, should a platform scenario play out, is anchored by the valuation of companies operating at the intersection of technology and therapeutic discovery. Recursion Pharmaceuticals, a publicly traded competitor applying automation and AI to drug discovery, has reached market capitalizations measured in billions of dollars [Crunchbase]. A more direct, though private, comparable is Formation Bio, which achieved a valuation likely in the hundreds of millions to low billions on the strength of its $372 million Series D round [Formation Bio]. If Foundational Bio executes on the platform partner scenario and captures a meaningful portion of a major pharma's external R&D budget, a valuation in the hundreds of millions of dollars is a plausible outcome (scenario, not a forecast). The cloud biofoundry standard scenario, while more speculative, points to an infrastructure-level outcome with a potential total addressable market measured against global R&D spend, which runs into the hundreds of billions annually.

Data Accuracy: YELLOW -- The opportunity framing is extrapolated from the company's stated mission and cited industry trends. Specific valuation comparables are from public sources.

Sources

PUBLIC

1. [Foundational Bio, retrieved 2024] Foundational Bio , https://foundational.bio/

2. [ScienceDirect, 2025] Cloud biofoundries and multi-AI agents advance self-driving labs via collaboration , https://www.sciencedirect.com/science/article/abs/pii/S001048252500123X

3. [Nature Reviews Drug Discovery, 2012] Diagnosing the decline in pharmaceutical R&D efficiency , https://www.nature.com/articles/nrd3681

4. [Grand View Research, 2024] Laboratory Automation Market Size, Share & Trends Analysis Report , https://www.grandviewresearch.com/industry-analysis/laboratory-automation-market

5. [MarketsandMarkets, 2023] AI in Drug Discovery Market , https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html

6. [FDA, 2023] Artificial Intelligence and Machine Learning in Drug Development , https://www.fda.gov/science-research/science-and-research-special-topics/artificial-intelligence-and-machine-learning-drug-development

7. [Formation Bio] Formation Bio | About Us , https://www.formation.bio/about-us

8. [Crunchbase] Recursion Pharmaceuticals - Crunchbase Company Profile & Funding , https://www.crunchbase.com/organization/recursion-pharmaceuticals

9. [Blank Bio] Blank Bio , https://www.blank.bio/